Biotechnology Industry | Healthcare Sector | - CEO | XSHE Exchange | CNE000000F14 ISIN |
China Country | 2,426 Employees | - Last Dividend | 27 Jul 2020 Last Split | - IPO Date |
Pacific Shuanglin Bio-pharmacy Co., Ltd., previously known as Southern Shuanglin Bio-pharmacy Co., Ltd., is a significant figure in China's biomedical sector, focusing on the research, development, production, and sales of blood products. Its foundation was laid in 1993, and in April 2021, it underwent a name change to reflect its broadened outlook and commitments. Based in Taiyuan, China, Pacific Shuanglin Bio-pharmacy Co., Ltd. not only concentrates on blood product manufacturing but also actively participates in the investment, consultation, and technological advancement of pharmaceutical and biotechnological development projects. Additionally, it offers electronic product information consultation, underlining its versatile approach to serving the healthcare and biopharmaceutical industries.
In addition to these leading products, Pacific Shuanglin Bio-pharmacy Co., Ltd. engages in the broader sphere of the pharmaceutical and biotechnological industry by participating in investment, consultation, and technology promotion projects. This holistic approach towards its business endeavors not only strengthens their product portfolio but also enhances their capabilities in providing comprehensive solutions in the biopharmaceutical domain, including electronic product information consultation services.